Clinical Trials in Meldola, Forlì-Cesena
11 recruiting
Showing 1–11 of 11 trials
Recruiting
Phase 3
A Study to Assess the Efficacy and Safety of Zipalertinib Versus Placebo for Adjuvant Treatment in Participants With Stage IB-IIIA NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection
Lung CancerEGFRNSCLC, Stage IB-IIIA+5 more
Taiho Oncology, Inc.360 enrolled253 locationsNCT07128199
Recruiting
Phase 3
Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.
MelanomaMetastatic MelanomaUnresectable Melanoma
Iovance Biotherapeutics, Inc.670 enrolled75 locationsNCT05727904
Recruiting
Phase 3
Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor
Patients With Non-small-cell Lung Cancer
OSE Immunotherapeutics363 enrolled207 locationsNCT06472245
Recruiting
Phase 2
Regorafenib for Recurrent Meningioma (MIRAGE Trial)
Meningioma, Malignant
Istituto Oncologico Veneto IRCCS104 enrolled17 locationsNCT06275919
Recruiting
Phase 1Phase 2
Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
Non-Small-Cell Lung Carcinoma
AbbVie252 enrolled55 locationsNCT06772623
Recruiting
Phase 3
Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer
Ovarian CancerFallopian Tube CancerPeritoneal Cancer
AbbVie520 enrolled264 locationsNCT05445778
Recruiting
PRostate Cancer Plasma Integrative Multi-modal Evaluation
Metastatic Prostate Cancer
Santa Chiara Hospital800 enrolled4 locationsNCT06981377
Recruiting
Phase 2
Safety and Efficacy of RVU120 Combined With Venetoclax for Treatment of Relapsed/Refractory AML
Acute Myeloid Leukemia
Ryvu Therapeutics SA98 enrolled37 locationsNCT06191263
Recruiting
A Machine Learning Approach to Connect Multiple Myeloma Complexity to Early Disease Recurrence
Multiple Myeloma (MM)
IRCCS Azienda Ospedaliero-Universitaria di Bologna200 enrolled4 locationsNCT06767254
Recruiting
Not Applicable
Integrative "Omics" Approaches for Leukemia Target Identification and Matched Therapeutic Intervention
Leukemia, Acute LymphoblasticMyeloid Leukemia, Acute
Azienda Ospedaliero-Universitaria di Parma100 enrolled8 locationsNCT06626893
Recruiting
Phase 2
"Receptor Radionuclide Therapy With 177Lu-DOTATOC
Neuroendocrine TumorsParagangliomaPheochromocytoma
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS100 enrolled2 locationsNCT06045260